Drug Patents owned by Baudax
1. List of Anjeso drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8512727 | BAUDAX | Nanoparticulate meloxicam formulations |
Dec, 2022
(3 months ago) | |
| US10463673 | BAUDAX | Nanoparticulate meloxicam formulations |
Feb, 2024
(10 months from now) | |
| US10471067 | BAUDAX | Nanoparticulate meloxicam formulations |
Feb, 2024
(10 months from now) | |
| US9974746 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(7 years from now) | |
| US10709713 | BAUDAX | Nanoparticulate meloxicam formulations |
May, 2030
(7 years from now) | |
| US11253478 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(7 years from now) | |
| US11458145 | BAUDAX | Methods of administering intravenous meloxicam in a bolus dose |
Mar, 2039
(15 years from now) | |
| US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild...
Dosage: SOLUTION;INTRAVENOUS
ANJESO family patents
28
United States
10
Japan
8
European Union
3
Canada
3
Spain
3
Australia
2
Hungary
2
Denmark
2
Korea, Republic of
2
China
1
Germany
1
Austria
1
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic